The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children
Not Applicable
Terminated
- Conditions
- Nausea
- Interventions
- Behavioral: Baxter Retching Faces (BARF) scale
- Registration Number
- NCT04678947
- Lead Sponsor
- Washington University School of Medicine
- Brief Summary
In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding administration of anti-emetic medications will be reviewed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Patients diagnosed with cancer of any kind.
- Patients receiving inpatient chemotherapy at SLCH on the general pediatric oncology service
- Patients admitted for a course of inpatient chemotherapy scheduled to last at least 24 hours and but no more than 7 days.
- Patients who have received any prior cancer treatment, including radiation therapy, and/or surgery.
- Patients ages 4 to 12 years of age.
- Patient with a guardian who has the ability to understand English and the willingness to sign an IRB approved written informed consent document.
Exclusion Criteria
- Any patient who is not undergoing inpatient chemotherapy on the general pediatric oncology service, including patients undergoing chemotherapy as conditioning for hematopoietic stem cell transplantation or other cellular therapy.
- Any patient who is receiving their first cycle of inpatient chemotherapy (however, they can be included during a future cycle).
- Any patient who is blind or unable to communicate by speaking or pointing.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BARF scale Baxter Retching Faces (BARF) scale * Nursing staff (which may include patient technicians and nursing assistants) will use the scale to assess the patient's nausea for the entire duration of the admission. These assessments will take place in conjunction with vital sign monitoring, every 4 hours. The associated script will be read while the laminated scale is shown to the patient. * The nurse will then log the patient's response in the patient's electronic medical record
- Primary Outcome Measures
Name Time Method Doses of anti-emetic medication administered during inpatient chemotherapy admissions 24 hours - 7 days (estimated)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States